PLoS ONE (Jan 2011)

MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes.

  • Elodie Lages,
  • Audrey Guttin,
  • Michèle El Atifi,
  • Claire Ramus,
  • Hélène Ipas,
  • Isabelle Dupré,
  • Delphine Rolland,
  • Caroline Salon,
  • Catherine Godfraind,
  • Florence deFraipont,
  • Mehdi Dhobb,
  • Laurent Pelletier,
  • Didier Wion,
  • Emmanuel Gay,
  • François Berger,
  • Jean-Paul Issartel

DOI
https://doi.org/10.1371/journal.pone.0020600
Journal volume & issue
Vol. 6, no. 5
p. e20600

Abstract

Read online

Gliomas such as oligodendrogliomas (ODG) and glioblastomas (GBM) are brain tumours with different clinical outcomes. Histology-based classification of these tumour types is often difficult. Therefore the first aim of this study was to gain microRNA data that can be used as reliable signatures of oligodendrogliomas and glioblastomas. We investigated the levels of 282 microRNAs using membrane-array hybridisation and real-time PCR in ODG, GBM and control brain tissues. In comparison to these control tissues, 26 deregulated microRNAs were identified in tumours and the tissue levels of seven microRNAs (miR-21, miR-128, miR-132, miR-134, miR-155, miR-210 and miR-409-5p) appropriately discriminated oligodendrogliomas from glioblastomas. Genomic, epigenomic and host gene expression studies were conducted to investigate the mechanisms involved in these deregulations. Another aim of this study was to better understand glioma physiopathology looking for targets of deregulated microRNAs. We discovered that some targets of these microRNAs such as STAT3, PTBP1 or SIRT1 are differentially expressed in gliomas consistent with deregulation of microRNA expression. Moreover, MDH1, the target of several deregulated microRNAs, is repressed in glioblastomas, making an intramitochondrial-NAD reduction mediated by the mitochondrial aspartate-malate shuttle unlikely. Understanding the connections between microRNAs and bioenergetic pathways in gliomas may lead to identification of novel therapeutic targets.